Aquinnah Pharmaceuticals is more recently shifted focused to a new area of research (for them) modulationof neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigâs disease. The firm is developing therapies to slow the progression of ALS and other neurodegenerative diseases to include, most recently, Alzheimers. Building on the work of founder Ben Wolozin, MD, PhD, 2013 recipient of the prestigious Zenith Fellows Award and chairman of the National Institutes of Health Cellular and Molecular Biology Neurodegeneration Study Section, the firm's drug-screening assays have identified excellent drug candidates with the potential to prevent and possibly reverse the formation of pathological stress granules
